Treatment of renal cell carcinoma
AssigneeBristol-Myers Squibb Company
InventorsJason Samuel Simon, Petra B. Ross-Macdonald
Life of this patent
Estimating the term…
Abstract
This disclosure provides methods for treating a subject afflicted with a tumor derived from a renal cell carcinoma. The methods comprise administering a first dose to a subject of an anti-PD-1 antibody or antigen-binding portion thereof and/or an anti-PD-L1 antibody or antigen-binding portion thereof, and administering a second dose to the subject, wherein the subject exhibited differential expression in one or more biomarker genes, e.g., CTLA-4, TIGIT, and/or PD-L2, following administration of the first dose.
Claims18
A method for treating a subject afflicted with a tumor derived from a renal cell carcinoma comprising:
- (i) administering a first dose of an anti-PD-1 antibody or an anti-PD-L1 antibody to the subject who exhibits an increased expression level of MICB, PVRIG, SPI1, CLEC2B, and NKG7 in a tumor biopsy obtained from the subject, relative to a reference expression level of MICB, PVRIG, SPI1, CLEC2B, and NKG7, wherein the reference expression level corresponds to the average expression level of MICB, PVRIG, SPI1, CLEC2B, and NKG7 as measured in tumor biopsies from a patient population affected with a tumor derived from a renal cell carcinoma;
- and
- (ii) administering a second dose of the anti-PD-1 antibody or the anti-PD-L1 antibody to the subject, wherein a tumor sample obtained from the subject exhibits an increased expression level of PVRIG, NKG7, CD244, NKTR, TNFSF8, TNFSF13B, TNFRSF14, SPI1, CLEC2B, CTLA-4, TIGIT, PD-L2, or any combination thereof on about day 8 after the administration of the first dose of the anti-PD-1 antibody or the anti-PD-L1 antibody, relative to the expression level of PVRIG, NKG7, CD244, NKTR, TNFSF8, TNFSF13B, TNFRSF14, SPI1, CLEC2B, CTLA-4, TIGIT, PD-L2, or any combination thereof in a tumor sample prior to the administration of the first dose of the anti-PD-1 antibody or the anti-PD-L1 antibody.
Dependencies are inferred from the claim text.